A Phase 1 interventional study of ONO-4578 and ONO-4538 in Advanced or Metastatic Solid Tumors, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 22 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
Drug: ONO-4578
ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
Drug: ONO-4578 · Drug: ONO-4538
ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
Drug: ONO-4578 · Drug: ONO-4538
ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer
Drug: ONO-4578 · Drug: ONO-4538
Evaluation of the safety (adverse event, clinical laboratory test, 12-lead electrocardiography, chest X-ray, ECOG performance status)
Time frame: Through study completion, an average of 1 year
Maximum observed serum concentration(Cmax)
Time frame: Up to Cycle 1 (each cycle is 28 days)
Area Under the blood concentration-time Curve(AUC)
Time frame: Up to Cycle 1 (each cycle is 28 days)
Half-life(T1/2) of ONO-4578 both alone and in combination with ONO-4538
Time frame: Up to Cycle 1 (each cycle is 28 days)
Plan to share: No
Started Apr 2017 (actual). Primary completion is estimated for Mar 2028, 131 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BMS-986310
Ono Pharmaceutical Co., Ltd. →